The acquisition brings closure for Mirati at last, though some investors will feel disappointed.

But a US adcom slams Amgen’s oversight of Codebreak-200, as the group’s KRAS rival Mirati surges on takeover talk.

Bristol, AbbVie and Jiangsu HengRui move to enter clinical trials with undisclosed mechanisms of action.

After touting NVL-655 as being active in patients resistant to a third-generation ALK inhibitor, Nuvalent now has clinical data to back this up.

But Repare and Black Diamond still have rebuilding to do.

After Exkivity signals another accelerated approval slowdown the Amgen drug tomorrow faces an adcom over its own conditional approval.

ALX Oncology claims the first ever success for a CD47 inhibitor in a global randomised solid tumour study.

With revumenib’s broader coverage Syndax tries to gain ground on Kura’s ziftomenib, but hits a new snag.

Beyond lung cancer this year’s ESMO promises several other late-breaking datasets that could change clinical practice.

And there won’t be a long to wait for the full data, with revelation that Mariposa features among numerous practice-changing late-breakers at ESMO.